These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10025924)

  • 21. Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis Study Group.
    Stevens W; Vancheeswaran R; Black CM
    Br J Rheumatol; 1992 Oct; 31(10):683-9. PubMed ID: 1393375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma.
    Clegg DO; Reading JC; Mayes MD; Seibold JR; Harris C; Wigley FM; Ward JR; Pisko EJ; Weisman MH; Lee P
    J Rheumatol; 1994 Jan; 21(1):105-10. PubMed ID: 8151563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variability of skin scores and clinical measurements in scleroderma.
    Pope JE; Baron M; Bellamy N; Campbell J; Carette S; Chalmers I; Dales P; Hanly J; Kaminska EA; Lee P
    J Rheumatol; 1995 Jul; 22(7):1271-6. PubMed ID: 7562757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
    Spiera R; Hummers L; Chung L; Frech TM; Domsic R; Hsu V; Furst DE; Gordon J; Mayes M; Simms R; Lafyatis R; Martyanov V; Wood T; Whitfield ML; Constantine S; Lee E; Dgetluck N; White B
    Arthritis Rheumatol; 2020 Aug; 72(8):1350-1360. PubMed ID: 32336038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
    Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
    Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
    Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
    Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
    Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
    Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
    Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
    Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
    Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.
    Kim D; Peck A; Santer D; Patole P; Schwartz SM; Molitor JA; Arnett FC; Elkon KB
    Arthritis Rheum; 2008 Jul; 58(7):2163-73. PubMed ID: 18576347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year.
    Biasi D; Carletto A; Caramaschi P; Zeminian S; Pacor ML; Corrocher R; Bambara LM
    Rev Rhum Engl Ed; 1998 Dec; 65(12):745-50. PubMed ID: 9923042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
    Chakravarty EF; Martyanov V; Fiorentino D; Wood TA; Haddon DJ; Jarrell JA; Utz PJ; Genovese MC; Whitfield ML; Chung L
    Arthritis Res Ther; 2015 Jun; 17(1):159. PubMed ID: 26071192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial.
    Zulian F; Martini G; Vallongo C; Vittadello F; Falcini F; Patrizi A; Alessio M; La Torre F; Podda RA; Gerloni V; Cutrone M; Belloni-Fortina A; Paradisi M; Martino S; Perilongo G
    Arthritis Rheum; 2011 Jul; 63(7):1998-2006. PubMed ID: 21305525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.
    Hulshof MM; Bouwes Bavinck JN; Bergman W; Masclee AA; Heickendorff L; Breedveld FC; Dijkmans BA
    J Am Acad Dermatol; 2000 Dec; 43(6):1017-23. PubMed ID: 11100017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth hormone substitution in growth hormone-deficient adults: effects on collagen type I synthesis and skin thickness.
    Kann P; Piepkorn B; Schehler B; Lotz J; Prellwitz W; Beyer J
    Exp Clin Endocrinol Diabetes; 1996; 104(4):327-33. PubMed ID: 8886750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.